Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

Cancer Cell

Volumn 29, Issue 5, 2016, Pages 639-652

  Zhang, Xing Ding ^a,b,c   Baladandayuthapani, Veerabhadran ^a   Lin, Heather ^a   Mulligan, George ^d   Li, Bin ^d   Esseltine, Dixie Lee W ^d   Qi, Lin ^c   Xu, Jianliang ^e   Hunziker, Walter ^e   Barlogie, Bart ^f   Usmani, Saad Z ^f,g   Zhang, Qing ^f,g   Crowley, John ^h   Hoering, Antje ^h   Shah, Jatin J ^a   Weber, Donna M ^a   Manasanch, Elisabet E ^a   Thomas, Sheeba K ^a   Li, Bing Zong ^a   Wang, Hui Han ^a   Zhang, Jiexin ^a   Kuiatse, Isere ^a   Tang, Jin Le ^b   Wang, Hua ^a   He, Jin ^a   Yang, Jing ^a   Milan, Enrico ⁱ   Cenci, Simone ⁱ   Ma, Wen Cai ^a   Wang, Zhi Qiang ^a   Davis, Richard Eric ^a   Yang, Lin ^b,c   Orlowski, Robert Z ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SOOCHOW UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g LEVINE CANCER INSTITUTE   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 1; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN ZO1; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; CYSTEINE PROTEINASE; EGFR PROTEIN, HUMAN; ERLOTINIB; JAK1 PROTEIN, HUMAN; LMP-2 PROTEIN; LMP7 PROTEIN; TJP1 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BORTEZOMIB; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 1; MICE, SCID; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84964619858     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.026     Document Type: Article

References (38)

1. Amit I., Citri A., Shay T., Lu Y., Katz M., Zhang F., Tarcic G., Siwak D., Lahad J., Jacob-Hirsch J., et al. A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 2007, 39:503-512.
2. Arneja A., Johnson H., Gabrovsek L., Lauffenburger D.A., White F.M. Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J. Immunol. 2014, 192:123-135.
3. Bianchi G., Oliva L., Cascio P., Pengo N., Fontana F., Cerruti F., Orsi A., Pasqualetto E., Mezghrani A., Calbi V., et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009, 113:3040-3049.
4. Bjorklund C.C., Ma W., Wang Z.Q., Davis R.E., Kuhn D.J., Kornblau S.M., Wang M., Shah J.J., Orlowski R.Z. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J. Biol. Chem. 2011, 286:11009-11020.
5. Bjorklund C.C., Baladandayuthapani V., Lin H.Y., Jones R.J., Kuiatse I., Wang H., Yang J., Shah J.J., Thomas S.K., Wang M., et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 2014, 28:373-383.
6. Borg J.P., Marchetto S., Le Bivic A., Ollendorff V., Jaulin-Bastard F., Saito H., Fournier E., Adelaide J., Margolis B., Birnbaum D. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat. Cell Biol. 2000, 2:407-414.
7. Cenci S., Mezghrani A., Cascio P., Bianchi G., Cerruti F., Fra A., Lelouard H., Masciarelli S., Mattioli L., Oliva L., et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006, 25:1104-1113.
8. Coldren C.D., Helfrich B.A., Witta S.E., Sugita M., Lapadat R., Zeng C., Baron A., Franklin W.A., Hirsch F.R., Geraci M.W., Bunn P.A. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol. Cancer Res. 2006, 4:521-528.
9. Deverson E.V., Gow I.R., Coadwell W.J., Monaco J.J., Butcher G.W., Howard J.C. MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature 1990, 348:738-741.
10. French J.D., Tschumper R.C., Jelinek D.F. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. Leukemia 2002, 16:1189-1196.
11. Hideshima T., Anderson K.C. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin. Hematol. 2012, 49:223-227.
12. Jones R.J., Baladandayuthapani V., Neelapu S., Fayad L.E., Romaguera J.E., Wang M., Sharma R., Yang D., Orlowski R.Z. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 2011, 118:4140-4149.
13. Kaihara T., Kawamata H., Imura J., Fujii S., Kitajima K., Omotehara F., Maeda N., Nakamura T., Fujimori T. Redifferentiation and ZO-1 reexpression in liver-metastasized colorectal cancer: possible association with epidermal growth factor receptor-induced tyrosine phosphorylation of ZO-1. Cancer Sci. 2003, 94:166-172.
14. Kobayashi S., Shimamura T., Monti S., Steidl U., Hetherington C.J., Lowell A.M., Golub T., Meyerson M., Tenen D.G., Shapiro G.I., Halmos B. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006, 66:11389-11398.
15. Kuhn D.J., Berkova Z., Jones R.J., Woessner R., Bjorklund C.C., Ma W., Davis R.E., Lin P., Wang H., Madden T.L., et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012, 120:3260-3270.
16. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
17. Leung-Hagesteijn C., Erdmann N., Cheung G., Keats J.J., Stewart A.K., Reece D.E., Chung K.C., Tiedemann R.E. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013, 24:289-304.
18. Li B., Fu J., Chen P., Ge X., Li Y., Kuiatse I., Wang H., Whang H., Zhang X., Orlowski R.Z. The nuclear factor (erythroid-derived 2)-like 2 and proteasome maturation protein axis mediates bortezomib resistance in multiple myeloma. J. Biol. Chem. 2015, 290:29854-29868.
19. Ligensa T., Krauss S., Demuth D., Schumacher R., Camonis J., Jaques G., Weidner K.M. A PDZ domain protein interacts with the C-terminal tail of the insulin-like growth factor-1 receptor but not with the insulin receptor. J. Biol. Chem. 2001, 276:33419-33427.
20. Lohr J.G., Stojanov P., Carter S.L., Cruz-Gordillo P., Lawrence M.S., Auclair D., Sougnez C., Knoechel B., Gould J., Saksena G., et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014, 25:91-101.
21. Mahtouk K., Jourdan M., De Vos J., Hertogh C., Fiol G., Jourdan E., Rossi J.F., Klein B. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004, 103:1829-1837.
22. Mahtouk K., Hose D., Reme T., De Vos J., Jourdan M., Moreaux J., Fiol G., Raab M., Jourdan E., Grau V., et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005, 24:3512-3524.
23. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T.A., Treon S.P., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 2002, 99:14374-14379.
24. Moreau P., Richardson P.G., Cavo M., Orlowski R.Z., San Miguel J.F., Palumbo A., Harousseau J.L. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120:947-959.
25. Mulligan G., Lichter D.I., Di Bacco A., Blakemore S.J., Berger A., Koenig E., Bernard H., Trepicchio W., Li B., Neuwirth R., et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014, 123:632-639.
26. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J. Immunol. 2007, 178:2623-2629.
27. O'Connor R., Ooi M.G., Meiller J., Jakubikova J., Klippel S., Delmore J., Richardson P., Anderson K., Clynes M., Mitsiades C.S., O'Gorman P. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother. Pharmacol. 2013, 71:1357-1368.
28. Orlowski R.Z. Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell 2013, 24:275-277.
29. Orlowski M., Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. 2000, 383:1-16.
30. Ortiz-Navarrete V., Seelig A., Gernold M., Frentzel S., Kloetzel P.M., Hammerling G.J. Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 1991, 353:662-664.
31. Podar K., Gouill S.L., Zhang J., Opferman J.T., Zorn E., Tai Y.T., Hideshima T., Amiot M., Chauhan D., Harousseau J.L., Anderson K.C. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 2008, 27:721-731.
32. Shah J.J., Orlowski R.Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009, 23:1964-1979.
33. Starmans M.H., Fung G., Steck H., Wouters B.G., Lambin P. A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One 2011, 6:e28320.
34. Takai E., Tan X., Tamori Y., Hirota M., Egami H., Ogawa M. Correlation of translocation of tight junction protein Zonula occludens-1 and activation of epidermal growth factor receptor in the regulation of invasion of pancreatic cancer cells. Int. J. Oncol. 2005, 27:645-651.
35. Venet D., Dumont J.E., Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput. Biol. 2011, 7:e1002240.
36. Walker B.A., Wardell C.P., Johnson D.C., Kaiser M.F., Begum D.B., Dahir N.B., Ross F.M., Davies F.E., Gonzalez D., Morgan G.J. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 2013, 121:3413-3419.
37. Wang Y.D., De Vos J., Jourdan M., Couderc G., Lu Z.Y., Rossi J.F., Klein B. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002, 21:2584-2592.
38. Xu J., Lim S.B., Ng M.Y., Ali S.M., Kausalya J.P., Limviphuvadh V., Maurer-Stroh S., Hunziker W. ZO-1 regulates Erk, Smad1/5/8, Smad2, and RhoA activities to modulate self-renewal and differentiation of mouse embryonic stem cells. Stem Cells 2012, 30:1885-1900.